Partial
Needs Revision
Patient Risk:
Moderate
Summary
Several claims match label excerpts provided (schizophrenia indication, subcutaneous administration requirement, and dementia-related psychosis mortality warning). However, many additional claims are unsupported or contradicted based on the provided label content, including asserted dosing intervals (monthly/every two months), mechanism details, side effect lists, geriatric restriction wording, cost/patent details, and incorrect statements about FDA limitations/approvals for other indications.
Category Scores
Accurate Statements
UZEDY (risperidone) is an extended-release injectable antipsychotic.
Section 11 Description and formulation description as extended-release injectable suspension (and Section 16/administration context).
UZEDY is approved by the FDA for treating schizophrenia in adults.
Section 1.1 Indications and Usage: "UZEDY is indicated for the treatment of schizophrenia in adults."
UZEDY is administered via subcutaneous injection.
Section 2.1: "must be administered ... as an abdominal or upper arm subcutaneous injection"; and "Do not administer ... by any other route."
UZEDY is not for elderly dementia patients due to increased death risk from heart issues or infections.
Section 5.1: "Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death." and "UZEDY is not approved for the treatment of patients with dementia-related psychosis."
Unsupported Statements
UZEDY delivers medication monthly or every two months.
No dosing interval information was provided in the supplied label excerpts.
UZEDY helps manage symptoms like hallucinations, delusions, and disorganized thinking in schizophrenia.
No symptom-level effect statements for schizophrenia were included in the supplied label excerpts.
Risperidone works by balancing dopamine and serotonin levels in the brain.
No mechanism of action description was included in the supplied label excerpts.
Risperidone reduces psychotic symptoms.
No specific efficacy/symptom claim text was included in the supplied label excerpts.
Risperidone stabilizes mood.
No mood-stabilizing claim text was included in the supplied label excerpts.
Clinical trials showed UZEDY matches oral risperidone's effectiveness.
No clinical trial comparative effectiveness text was included in the supplied label excerpts.
Clinical trials showed UZEDY improves adherence due to less frequent dosing.
No adherence/dosing-frequency trial claim text was included in the supplied label excerpts.
UZEDY does not require daily pills.
The supplied excerpts do not state administration frequency relative to oral daily dosing.
The FDA label for UZEDY limits its indication to schizophrenia.
Supplied excerpts show an additional FDA indication: maintenance treatment of Bipolar I Disorder in adults (Section 1.2).
UZEDY lacks FDA approvals for bipolar mania and irritability in autism.
No autism or bipolar mania/irritability claims were provided in the supplied label excerpts to verify this.
Off-label use for other conditions like bipolar disorder occurs.
No label text was provided to support or reference real-world off-label use.
Off-label use of UZEDY for conditions other than schizophrenia is not FDA-endorsed.
The label excerpt does not address off-label use behavior; also the label includes at least one other FDA-approved use (Bipolar I maintenance).
Common side effects of UZEDY include weight gain.
No adverse reaction list was included in the supplied label excerpts.
Common side effects of UZEDY include drowsiness.
No adverse reaction list was included in the supplied label excerpts.
Common side effects of UZEDY include injection-site reactions.
No adverse reaction list was included in the supplied label excerpts.
Common side effects of UZEDY include movement disorders like tremors.
No adverse reaction list was included in the supplied label excerpts.
Long-term risks of UZEDY include elevated blood sugar.
No long-term risk list was included in the supplied label excerpts.
Long-term risks of UZEDY include high cholesterol.
No long-term risk list was included in the supplied label excerpts.
Long-term risks of UZEDY include tardive dyskinesia.
No long-term risk list was included in the supplied label excerpts.
UZEDY provides steady release for better compliance compared with daily oral antipsychotics.
No formulation or compliance comparison text was included in the supplied label excerpts.
Competitor Invega Hafyera (paliperidone) provides six-month dosing.
Not part of the supplied UZEDY label excerpts.
UZEDY is described as pricier upfront (~$2,000-$3,000 per injection).
No pricing information was included in the supplied label excerpts.
UZEDY may cut long-term costs via fewer clinic visits.
No health economics/cost claim text was included in the supplied label excerpts.
Teva Pharmaceuticals and MedinCell developed UZEDY.
No developer/manufacturer history was included in the supplied label excerpts.
UZEDY was launched in 2023.
No launch/approval year information was included in the supplied label excerpts.
Key patents for UZEDY cover a Steady-state Technology delivery system.
No patent/technology description was included in the supplied label excerpts.
U.S. Patent No. 10,987,410 expires around 2038.
No patent expiration information was included in the supplied label excerpts.
Contradictions
Low
AI Statement
The FDA label for UZEDY limits its indication to schizophrenia.
Label Reference
Section 1.2 Indications and Usage: UZEDY is also indicated for maintenance treatment of Bipolar I Disorder in adults.
Low
AI Statement
UZEDY lacks FDA approvals for bipolar mania and irritability in autism.
Label Reference
Section 1.2 shows FDA indication for maintenance treatment of Bipolar I Disorder in adults (adjunctive to lithium or valproate). The excerpt does not address autism/irritability; the broad "lacks FDA approvals" statement conflicts with the presence of a Bipolar I indication.
Important Omissions
No label-supported contraindication statement/hypersensitivity claim was evaluated (e.g., hypersensitivity to risperidone/paliperidone/components) despite providing a contraindications section in the label excerpt.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Some safety-critical elements were correctly referenced (increased mortality in elderly patients with dementia-related psychosis; UZEDY not approved for that population). However, multiple other claims that could influence use/dosing/side-effect expectations were unsupported, and several indication-related statements conflicted with the label (additional Bipolar I maintenance indication).
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Needs Revision
Primary Issue
Many claims are not supported by the provided label excerpts (notably dosing intervals, adverse reactions, mechanism/efficacy specifics, and economic/patent facts) and one major indication-limitation claim conflicts with the label (Bipolar I maintenance indication).
Suggested Improvement
Restrict statements to label-supported content from the supplied excerpts (Section 1.1 schizophrenia indication; Section 1.2 Bipolar I maintenance; Section 2.1 subcutaneous administration by healthcare professional and route restriction; Sections 5.1/5.2/8.5 dementia-related psychosis mortality warnings; Section 4 hypersensitivity contraindication). Remove or qualify unsupported dosing-interval, adverse-effect, mechanism, and non-label business/patent/pricing claims.